129 related articles for article (PubMed ID: 34913834)
1.
Säll C; Fogt Hjorth C
Xenobiotica; 2022 Jan; 52(1):1-15. PubMed ID: 34913834
[TBL] [Abstract][Full Text] [Related]
2. In Vitro Interaction of Tetrahydrouridine with Key Human Nucleoside Transporters.
Säll C; Koncsos G; Klukovits A
J Pharm Sci; 2023 Oct; 112(10):2676-2684. PubMed ID: 37364771
[TBL] [Abstract][Full Text] [Related]
3. Oral tetrahydrouridine and decitabine for non-cytotoxic epigenetic gene regulation in sickle cell disease: A randomized phase 1 study.
Molokie R; Lavelle D; Gowhari M; Pacini M; Krauz L; Hassan J; Ibanez V; Ruiz MA; Ng KP; Woost P; Radivoyevitch T; Pacelli D; Fada S; Rump M; Hsieh M; Tisdale JF; Jacobberger J; Phelps M; Engel JD; Saraf S; Hsu LL; Gordeuk V; DeSimone J; Saunthararajah Y
PLoS Med; 2017 Sep; 14(9):e1002382. PubMed ID: 28880867
[TBL] [Abstract][Full Text] [Related]
4. In vitro evaluation of potential drug interactions mediated by cytochrome P450 and transporters for luseogliflozin, an SGLT2 inhibitor.
Chino Y; Hasegawa M; Fukasawa Y; Mano Y; Bando K; Miyata A; Nakai Y; Endo H; Yamaguchi JI
Xenobiotica; 2017 Apr; 47(4):314-323. PubMed ID: 27324291
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and pharmacodynamics of an oral formulation of decitabine and tetrahydrouridine.
Lau H; Woost PG; Friedrich U; Clausen WHO; Jacobberger JW; Saunthararajah Y
Eur J Haematol; 2023 Sep; 111(3):345-355. PubMed ID: 37417197
[TBL] [Abstract][Full Text] [Related]
6. Raltegravir has a low propensity to cause clinical drug interactions through inhibition of major drug transporters: an in vitro evaluation.
Rizk ML; Houle R; Chan GH; Hafey M; Rhee EG; Chu X
Antimicrob Agents Chemother; 2014; 58(3):1294-301. PubMed ID: 24295974
[TBL] [Abstract][Full Text] [Related]
7. Novel Bruton's tyrosine kinase inhibitor remibrutinib: Assessment of drug-drug interaction potential as a perpetrator of cytochrome P450 enzymes and drug transporters and the impact of covalent binding on possible drug interactions.
Schiller H; Huth F; Schuhler C; Drollmann A; Kaul M; Woessner R; Shah B; Weis W; End P
Eur J Pharm Sci; 2022 May; 172():106155. PubMed ID: 35247543
[TBL] [Abstract][Full Text] [Related]
8. A pilot clinical trial of oral tetrahydrouridine/decitabine for noncytotoxic epigenetic therapy of chemoresistant lymphoid malignancies.
Hill B; Jagadeesh D; Pohlman B; Dean R; Parameswaran N; Chen J; Radivoyevitch T; Morrison A; Fada S; Dever M; Robinson S; Lindner D; Smith M; Saunthararajah Y
Semin Hematol; 2021 Jan; 58(1):35-44. PubMed ID: 33509441
[TBL] [Abstract][Full Text] [Related]
9. In vitro cytochrome P450- and transporter-mediated drug interaction potential of 6β-hydroxy-21-desacetyl deflazacort-A major human metabolite of deflazacort.
Ma J; Beers B; Manohar R; Roe S; Colacino JM; Kong R
Pharmacol Res Perspect; 2021 Apr; 9(2):e00748. PubMed ID: 33749127
[TBL] [Abstract][Full Text] [Related]
10. Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: a simulation assessment using the "Advanced Dissolution, Absorption, Metabolism (ADAM)" model.
Darwich AS; Neuhoff S; Jamei M; Rostami-Hodjegan A
Curr Drug Metab; 2010 Nov; 11(9):716-29. PubMed ID: 21189140
[TBL] [Abstract][Full Text] [Related]
11. An Assessment of the In Vitro Inhibition of Cytochrome P450 Enzymes, UDP-Glucuronosyltransferases, and Transporters by Phosphodiester- or Phosphorothioate-Linked Oligonucleotides.
Kazmi F; Yerino P; McCoy C; Parkinson A; Buckley DB; Ogilvie BW
Drug Metab Dispos; 2018 Aug; 46(8):1066-1074. PubMed ID: 29735754
[TBL] [Abstract][Full Text] [Related]
12. Potential of the novel antiretroviral drug rilpivirine to modulate the expression and function of drug transporters and drug-metabolising enzymes in vitro.
Weiss J; Haefeli WE
Int J Antimicrob Agents; 2013 May; 41(5):484-7. PubMed ID: 23428312
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic drug interactions involving 17alpha-ethinylestradiol: a new look at an old drug.
Zhang H; Cui D; Wang B; Han YH; Balimane P; Yang Z; Sinz M; Rodrigues AD
Clin Pharmacokinet; 2007; 46(2):133-57. PubMed ID: 17253885
[TBL] [Abstract][Full Text] [Related]
14. Interaction potential of the endothelin-A receptor antagonist atrasentan with drug transporters and drug-metabolising enzymes assessed in vitro.
Weiss J; Haefeli WE
Cancer Chemother Pharmacol; 2011 Oct; 68(4):1093-8. PubMed ID: 21805352
[TBL] [Abstract][Full Text] [Related]
15. The Use of Transporter Probe Drug Cocktails for the Assessment of Transporter-Based Drug-Drug Interactions in a Clinical Setting-Proposal of a Four Component Transporter Cocktail.
Ebner T; Ishiguro N; Taub ME
J Pharm Sci; 2015 Sep; 104(9):3220-8. PubMed ID: 25981193
[TBL] [Abstract][Full Text] [Related]
16. In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor.
Reese MJ; Savina PM; Generaux GT; Tracey H; Humphreys JE; Kanaoka E; Webster LO; Harmon KA; Clarke JD; Polli JW
Drug Metab Dispos; 2013 Feb; 41(2):353-61. PubMed ID: 23132334
[TBL] [Abstract][Full Text] [Related]
17. In Vitro Inhibitory Effects of APINACA on Human Major Cytochrome P450, UDP-Glucuronosyltransferase Enzymes, and Drug Transporters.
Kim S; Choi WG; Kwon M; Lee S; Cho YY; Lee JY; Kang HC; Song IS; Lee HS
Molecules; 2019 Aug; 24(16):. PubMed ID: 31430908
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, and pharmacological evaluation of fluorinated tetrahydrouridine derivatives as inhibitors of cytidine deaminase.
Ferraris D; Duvall B; Delahanty G; Mistry B; Alt J; Rojas C; Rowbottom C; Sanders K; Schuck E; Huang KC; Redkar S; Slusher BB; Tsukamoto T
J Med Chem; 2014 Mar; 57(6):2582-8. PubMed ID: 24520856
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of
Liao M; Jaw-Tsai S; Beltman J; Simmons AD; Harding TC; Xiao JJ
Xenobiotica; 2020 Sep; 50(9):1032-1042. PubMed ID: 32129697
[TBL] [Abstract][Full Text] [Related]
20. In vitro and physiologically-based pharmacokinetic based assessment of drug-drug interaction potential of canagliflozin.
Mamidi RNVS; Dallas S; Sensenhauser C; Lim HK; Scheers E; Verboven P; Cuyckens F; Leclercq L; Evans DC; Kelley MF; Johnson MD; Snoeys J
Br J Clin Pharmacol; 2017 May; 83(5):1082-1096. PubMed ID: 27862160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
